By Monica Heger

Intelligent Bio-Systems is developing a low-cost sequencing system that it claims is particularly suited for the clinical market and plans to commercially launch the system in 2012.

Steven Gordon, CEO of Waltham, Mass.-based IBS, disclosed the company's plans for the system at this month's X-Gen Congress meeting in San Diego. He said the company plans to line up early-access customers in the third or fourth quarter of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.